Literature DB >> 12134631

[Regulation of human neutrophil oxidative burst by pro- and anti-inflammatory cytokines].

M A Gougerot-Pocidalo1, J el Benna, C Elbim, S Chollet-Martin, M C Dang.   

Abstract

Human polymorphonuclear neutrophils play a key role in host defenses against invading microorganisms. In response to a variety of stimuli, neutrophils release large quantities of superoxide anion (O2.-) in a phenomenon known as the respiratory burst. O2.- is the precursor of potent oxidants, which are essential for bacterial killing and also potentiate inflammatory reactions. Regulation of this production is therefore critical to kill pathogens without inducing tissue injury. Neutrophil production of O2.- is dependent on the respiratory burst oxidase, or NADPH oxidase, a multicomponent enzyme system that catalyzes NADPH-dependent reduction of oxygen to O2.-. NADPH oxidase is activated and regulated by various neutrophil stimuli at infectious or inflammatory sites. Proinflammatory cytokines such as GM-CSF, TNF and IL-8 modulate NADPH oxidase activity through a priming phenomenon. These cytokines induce a very weak oxidative response by PMN but strongly enhance neutrophil release of reactive oxygen species on exposure to a secondary applied stimulus such as bacterial N-formyl peptides. Priming phenomena are involved in normal innate immune defense and in some inflammatory diseases. The mechanisms underlying the priming process are poorly understood, although some studies have suggested that priming with various agonists is regulated at the receptor and post-receptor levels. Resolution of inflammation involves desensitization phenomena and cytokines are involved in this process by various mechanisms. A better understanding of phenomena involved in the regulation of NADPH oxidase could help to develop novel therapeutic agents for inflammatory diseases involving abnormal neutrophil superoxide production.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134631

Source DB:  PubMed          Journal:  J Soc Biol        ISSN: 1295-0661


  6 in total

1.  Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.

Authors:  Letizia Crocetti; Claudia Vergelli; Gabriella Guerrini; Niccolò Cantini; Liliya N Kirpotina; Igor A Schepetkin; Mark T Quinn; Carmen Parisio; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Maria Paola Giovannoni
Journal:  Bioorg Chem       Date:  2020-04-28       Impact factor: 5.275

2.  Influence of PMN leukocyte-mediated pancreatic damage on the systemic immune response in severe acute pancreatitis in rats.

Authors:  Uwe A Wittel; Bettina Rau; Frank Gansauge; Susanne Gansauge; Andreas K Nussler; Hans G Beger; Bertram Poch
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

3.  Novel program of macrophage gene expression induced by phagocytosis of Leishmania chagasi.

Authors:  Nilda E Rodriguez; Haeok K Chang; Mary E Wilson
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

4.  Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response.

Authors:  Annalucia Serafino; Paola Sinibaldi Vallebona; Federica Andreola; Manuela Zonfrillo; Luana Mercuri; Memmo Federici; Guido Rasi; Enrico Garaci; Pasquale Pierimarchi
Journal:  BMC Immunol       Date:  2008-04-18       Impact factor: 3.615

5.  Prostate cancer addiction to oxidative stress defines sensitivity to anti-tumor neutrophils.

Authors:  Diane L Costanzo-Garvey; Adam J Case; Gabrielle F Watson; Massar Alsamraae; Arpita Chatterjee; Rebecca E Oberley-Deegan; Samikshan Dutta; Maher Y Abdalla; Tammy Kielian; Merry L Lindsey; Leah M Cook
Journal:  Clin Exp Metastasis       Date:  2022-05-23       Impact factor: 4.510

6.  Differential effects of antibiotics in combination with G-CSF on survival and polymorphonuclear granulocyte cell functions in septic rats.

Authors:  Artur Bauhofer; Markus Huttel; Wilfried Lorenz; Daniel I Sessler; Alexander Torossian
Journal:  BMC Infect Dis       Date:  2008-04-30       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.